Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gen
AbstractJAK inhibitors are important therapeutic options for hematological disorders, especially mye...
Objective: Philadelphia-negative myeloproliferative neoplasms (MPNs) commonly share hyperactive JAK-...
Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% o...
Abstract The myeloproliferative neoplasms (MPN), polycythaemia vera (PV), essential thrombocythemia ...
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and p...
BACKGROUND: This review summarizes the case studies of PCM1-JAK2 fusion tyrosine kinase gene-related...
Rearrangements of chromosome band 9p24 are known to be associated with JAK2 fusion genes, e.g., t(8;...
The response of myeloproliferative neoplasms with PCM1-JAK2 fusion genes can be long-lived, without...
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approxi...
Abstract: Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malig...
Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolit...
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis...
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical prese...
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patien...
Robyn M Emanuel,1 Holly L Geyer,1 Ruben A Mesa2 1Department of Internal Medicine, 2Department of Hem...
AbstractJAK inhibitors are important therapeutic options for hematological disorders, especially mye...
Objective: Philadelphia-negative myeloproliferative neoplasms (MPNs) commonly share hyperactive JAK-...
Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% o...
Abstract The myeloproliferative neoplasms (MPN), polycythaemia vera (PV), essential thrombocythemia ...
Myeloproliferative neoplasms (MPNs) include essential thrombocythemia, polycythemia vera (PV), and p...
BACKGROUND: This review summarizes the case studies of PCM1-JAK2 fusion tyrosine kinase gene-related...
Rearrangements of chromosome band 9p24 are known to be associated with JAK2 fusion genes, e.g., t(8;...
The response of myeloproliferative neoplasms with PCM1-JAK2 fusion genes can be long-lived, without...
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approxi...
Abstract: Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malig...
Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor ruxolit...
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis...
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical prese...
Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patien...
Robyn M Emanuel,1 Holly L Geyer,1 Ruben A Mesa2 1Department of Internal Medicine, 2Department of Hem...
AbstractJAK inhibitors are important therapeutic options for hematological disorders, especially mye...
Objective: Philadelphia-negative myeloproliferative neoplasms (MPNs) commonly share hyperactive JAK-...
Myeloproliferative neoplasms (MPNs) are diseases that carry the JAK2 (V617F) mutation in about 70% o...
DOI
Add to ORKG